The OnTarget study is a Phase 3, multicenter clinical trial (Protocol NP303-102)
evaluating the safety and effectiveness of crofelemer in cancer therapy-related diarrhea in
adult patients with solid tumors.
Napo Pharmaceuticals, Inc.
200 Pine Street, Suite 400
San Francisco, CA 94104
©2023 Napo Pharmaceuticals, Inc.
MYTESI® CALL CENTER
For product information, adverse event
reports, and product complaint reports,
please contact the Mytesi® Call Center at
(844) 722-8256 or by email at
Web Accessibility Feedback Email
Web Accessibility Feedback Form
©2023 Napo Pharmaceuticals Inc.